Sake J. van der Wall

Continuation of low‐molecular‐weight heparin treatment for cancer‐related venous thromboembolism: a prospective cohort study in daily clinical practice

Sake J. van der Wall, Frederikus A. Klok, Paul L. den Exter et al. · Journal of Thrombosis and Haemostasis · 2016 · 63 citations

Thrombosis, Daily Clinical Practice, Venous Thrombosis +8

Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding

Sake J. van der Wall, Renato D. Lópes, James Aisenberg et al. · Circulation · 2019 · 48 citations

Performance of idarucizumab as antidote of dabigatran in daily clinical practice

Sake J. van der Wall, Nienke van Rein, Bart J. F. van den Bemt et al. · EP Europace · 2018 · 38 citations · Full text

Antithrombotic therapy after mitral valve repair: VKA or aspirin?

Sake J. van der Wall, Jules R. Olsthoorn, Samuel Heuts et al. · Journal of Thrombosis and Thrombolysis · 2018 · 32 citations · Full text

Bleeding Complications, Adult Cardiac Surgery, Antithrombotic Therapy +20

Higher Adherence to Treatment With Low‐Molecular‐Weight‐Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer‐Associated Venous Thromboembolism

Sake J. van der Wall, Frederikus A. Klok, Paul L. den Exter et al. · HemaSphere · 2018 · 10 citations · Full text

Active Cancer, Higher Adherence, Pharmacotherapy +16